FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303411526> ?p ?o ?g. }

• W4303411526 abstract "Background Until recently there were no genome-directed therapies (GDTs) requiring next-generation sequencing (NGS) in prostate cancer. We examined whether the US approval of poly-(ADP-ribose) polymerase (PARP) inhibitors in May 2020 influenced the actionability and utilization of NGS in patients with prostate cancer. Methods This was a single-center, retrospective study including men with prostate cancer who received NGS testing from a single lab between 7/11/2018-7/6/2021. Clinical and testing data were derived from the electronic medical record. Results There were 346 patients with prostate cancer and qualifying NGS testing during the study period. Overall, 55 patients (15.9%) had qualifying homologous recombination repair (HRR) alterations for PARP inhibitor treatment. A greater proportion of alterations were actionable post-approval compared to pre-approval (22.7% vs 0%, Chi-squared p&lt;0.001). 9 patients received olaparib during the study period. Patients receiving NGS testing after the PARP inhibitor approval were more likely to have metastatic disease than patients sequenced before the approval (74.2% vs. 41.1% Chi-squared p&lt;0.001). Only 10.4% of patients with metastatic prostate cancer received NGS testing within 30 days of diagnosis. NGS testing was performed after a median of 1 prior line of systemic therapy. The median number of days between metastatic diagnosis and NGS testing was 196 (Q1-Q3: 54-832). The median time from NGS testing to the next treatment was 255 days (95% CI 151-300). These characteristics were not significantly different before or after the PARP inhibitor approval. Conclusion In this single-center cohort, the approval of PARP inhibitors for later-line treatment of metastatic prostate cancer increased the actionability of NGS findings but did not lead to earlier use of NGS testing." @default.
• W4303411526 created "2022-10-07" @default.
• W4303411526 creator A5002214778 @default.
• W4303411526 creator A5018275141 @default.
• W4303411526 creator A5019774807 @default.
• W4303411526 creator A5021691020 @default.
• W4303411526 creator A5028201251 @default.
• W4303411526 creator A5044784902 @default.
• W4303411526 creator A5050320394 @default.
• W4303411526 creator A5059178256 @default.
• W4303411526 creator A5063074565 @default.
• W4303411526 creator A5063514061 @default.
• W4303411526 creator A5071318362 @default.
• W4303411526 creator A5075136340 @default.
• W4303411526 creator A5078027978 @default.
• W4303411526 creator A5089011631 @default.
• W4303411526 date "2022-10-06" @default.
• W4303411526 modified "2023-09-30" @default.
• W4303411526 title "Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape" @default.
• W4303411526 cites W1578291413 @default.
• W4303411526 cites W2566723262 @default.
• W4303411526 cites W2620706965 @default.
• W4303411526 cites W2792228174 @default.
• W4303411526 cites W2802321540 @default.
• W4303411526 cites W2888034354 @default.
• W4303411526 cites W2896490588 @default.
• W4303411526 cites W2943781197 @default.
• W4303411526 cites W2944403040 @default.
• W4303411526 cites W2977196140 @default.
• W4303411526 cites W3020771563 @default.
• W4303411526 cites W3025106418 @default.
• W4303411526 cites W3041912701 @default.
• W4303411526 cites W3049351332 @default.
• W4303411526 cites W3097971145 @default.
• W4303411526 cites W3112425050 @default.
• W4303411526 cites W3133328851 @default.
• W4303411526 cites W3134085117 @default.
• W4303411526 cites W3163184536 @default.
• W4303411526 cites W3166501127 @default.
• W4303411526 cites W3185901305 @default.
• W4303411526 cites W4212780237 @default.
• W4303411526 cites W4226431051 @default.
• W4303411526 cites W4281770555 @default.
• W4303411526 doi "https://doi.org/10.3389/fruro.2022.997396" @default.
• W4303411526 hasPublicationYear "2022" @default.
• W4303411526 type Work @default.
• W4303411526 citedByCount "0" @default.
• W4303411526 crossrefType "journal-article" @default.
• W4303411526 hasAuthorship W4303411526A5002214778 @default.
• W4303411526 hasAuthorship W4303411526A5018275141 @default.
• W4303411526 hasAuthorship W4303411526A5019774807 @default.
• W4303411526 hasAuthorship W4303411526A5021691020 @default.
• W4303411526 hasAuthorship W4303411526A5028201251 @default.
• W4303411526 hasAuthorship W4303411526A5044784902 @default.
• W4303411526 hasAuthorship W4303411526A5050320394 @default.
• W4303411526 hasAuthorship W4303411526A5059178256 @default.
• W4303411526 hasAuthorship W4303411526A5063074565 @default.
• W4303411526 hasAuthorship W4303411526A5063514061 @default.
• W4303411526 hasAuthorship W4303411526A5071318362 @default.
• W4303411526 hasAuthorship W4303411526A5075136340 @default.
• W4303411526 hasAuthorship W4303411526A5078027978 @default.
• W4303411526 hasAuthorship W4303411526A5089011631 @default.
• W4303411526 hasBestOaLocation W43034115261 @default.
• W4303411526 hasConcept C121608353 @default.
• W4303411526 hasConcept C126322002 @default.
• W4303411526 hasConcept C143998085 @default.
• W4303411526 hasConcept C182979987 @default.
• W4303411526 hasConcept C2776235491 @default.
• W4303411526 hasConcept C2779138821 @default.
• W4303411526 hasConcept C2779962180 @default.
• W4303411526 hasConcept C2780192828 @default.
• W4303411526 hasConcept C54355233 @default.
• W4303411526 hasConcept C552990157 @default.
• W4303411526 hasConcept C71924100 @default.
• W4303411526 hasConcept C82381507 @default.
• W4303411526 hasConcept C86803240 @default.
• W4303411526 hasConceptScore W4303411526C121608353 @default.
• W4303411526 hasConceptScore W4303411526C126322002 @default.
• W4303411526 hasConceptScore W4303411526C143998085 @default.
• W4303411526 hasConceptScore W4303411526C182979987 @default.
• W4303411526 hasConceptScore W4303411526C2776235491 @default.
• W4303411526 hasConceptScore W4303411526C2779138821 @default.
• W4303411526 hasConceptScore W4303411526C2779962180 @default.
• W4303411526 hasConceptScore W4303411526C2780192828 @default.
• W4303411526 hasConceptScore W4303411526C54355233 @default.
• W4303411526 hasConceptScore W4303411526C552990157 @default.
• W4303411526 hasConceptScore W4303411526C71924100 @default.
• W4303411526 hasConceptScore W4303411526C82381507 @default.
• W4303411526 hasConceptScore W4303411526C86803240 @default.
• W4303411526 hasLocation W43034115261 @default.
• W4303411526 hasOpenAccess W4303411526 @default.
• W4303411526 hasPrimaryLocation W43034115261 @default.
• W4303411526 hasRelatedWork W1980245127 @default.
• W4303411526 hasRelatedWork W2755661377 @default.
• W4303411526 hasRelatedWork W2968363820 @default.
• W4303411526 hasRelatedWork W3044648685 @default.
• W4303411526 hasRelatedWork W3156635054 @default.
• W4303411526 hasRelatedWork W3164096504 @default.
• W4303411526 hasRelatedWork W3188692221 @default.
• W4303411526 hasRelatedWork W3208352425 @default.

• next